382 related articles for article (PubMed ID: 30863934)
1. Is there a difference in regional read [
Farrar G; Molinuevo JL; Zanette M
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1299-1308. PubMed ID: 30863934
[TBL] [Abstract][Full Text] [Related]
2. Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers.
Miki T; Shimada H; Kim JS; Yamamoto Y; Sugino M; Kowa H; Heurling K; Zanette M; Sherwin PF; Senda M
Ann Nucl Med; 2017 Apr; 31(3):260-272. PubMed ID: 28181118
[TBL] [Abstract][Full Text] [Related]
3. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
[TBL] [Abstract][Full Text] [Related]
4. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
6. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
[TBL] [Abstract][Full Text] [Related]
7. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
8. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
[TBL] [Abstract][Full Text] [Related]
9. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
[TBL] [Abstract][Full Text] [Related]
10. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease.
Imabayashi E; Tamamura N; Yamaguchi Y; Kamitaka Y; Sakata M; Ishii K
Ann Nucl Med; 2022 Oct; 36(10):865-875. PubMed ID: 35821311
[TBL] [Abstract][Full Text] [Related]
11. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [
Bucci M; Savitcheva I; Farrar G; Salvadó G; Collij L; Doré V; Gispert JD; Gunn R; Hanseeuw B; Hansson O; Shekari M; Lhommel R; Molinuevo JL; Rowe C; Sur C; Whittington A; Buckley C; Nordberg A
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2183-2199. PubMed ID: 33844055
[TBL] [Abstract][Full Text] [Related]
12. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease.
Duara R; Loewenstein DA; Shen Q; Barker W; Potter E; Varon D; Heurlin K; Vandenberghe R; Buckley C
Alzheimers Dement; 2013 May; 9(3):295-301. PubMed ID: 23178035
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal cognitive decline in mild cognitive impairment subjects with early amyloid-β neocortical deposition.
Ciarmiello A; Giovannini E; Riondato M; Giovacchini G; Duce V; Ferrando O; De Biasi M; Passera C; Carabelli E; Mannironi A; Mansi L; Tartaglione A
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2090-2098. PubMed ID: 31264171
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of [
Leuzy A; Savitcheva I; Chiotis K; Lilja J; Andersen P; Bogdanovic N; Jelic V; Nordberg A
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1276-1286. PubMed ID: 30915522
[TBL] [Abstract][Full Text] [Related]
15. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.
Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T;
Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127
[TBL] [Abstract][Full Text] [Related]
17. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
18. Cognitive trajectories of patients with focal ß-amyloid deposition.
Kim SE; Lee B; Jang H; Chin J; Khoo CS; Choe YS; Kim JS; Kang SH; Kim HR; Hwangbo S; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Jang JW; Hong JY; Na DL; Seo SW; Choi SH; Kim HJ
Alzheimers Res Ther; 2021 Feb; 13(1):48. PubMed ID: 33608041
[TBL] [Abstract][Full Text] [Related]
19. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
